Dexmedetomidine is neuroprotective in an in vitro model for traumatic brain injury

BMC Neurology

Volumn 12, Issue , 2012, Pages

  Schoeler, Marc ^a   Loetscher, Philip D ^a   Rossaint, Rolf ^a   Fahlenkamp, Astrid V ^a   Eberhardt, Georg ^a   Rex, Steffen ^a,b   Weis, Joachim ^a   Coburn, Mark ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Dexmedetomidine; Neuroprotection; Traumatic brain injury

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; DEXMEDETOMIDINE; NEUROPROTECTIVE AGENT; PROPIDIUM IODIDE; ENZYME INHIBITOR; FLAVONOID;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HYPOTHERMIA; IN VITRO STUDY; MOUSE; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; SIGNAL TRANSDUCTION; TRAUMATIC BRAIN INJURY; ANALYSIS OF VARIANCE; ANIMAL; BRAIN INJURY; C57BL MOUSE; CELL COUNT; DISEASE MODEL; DRUG ADMINISTRATION; HIPPOCAMPUS; INDUCED HYPOTHERMIA; METHODOLOGY; NEWBORN; ORGAN CULTURE TECHNIQUE; PATHOLOGY; TIME;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; BRAIN INJURIES; CELL COUNT; DEXMEDETOMIDINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FLAVONOIDS; HIPPOCAMPUS; HYPOTHERMIA, INDUCED; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; ORGAN CULTURE TECHNIQUES; TIME FACTORS;

EID: 84859503661     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-12-20     Document Type: Article

References (29)

1. Corrigan JD, Selassie AW, Orman JA. The epidemiology of traumatic brain injury. J Head Trauma Rehabil 2010, 25:72-80. 10.1097/HTR.0b013e3181ccc8b4, 20234226.
2. Selassie AW, Zaloshnja E, Langlois JA, Miller T, Jones P, Steiner C. Incidence of long-term disability following traumatic brain injury hospitalization, United States, 2003. J Head Trauma Rehabil 2008, 23:123-131. 10.1097/01.HTR.0000314531.30401.39, 18362766.
3. Thurman DJ, Alverson C, Dunn KA, Guerrero J, Sniezek JE. Traumatic brain injury in the United States: a public health perspective. J Head Trauma Rehabil 1999, 14:602-615. 10.1097/00001199-199912000-00009, 10671706.
4. Hoffman WE, Kochs E, Werner C, Thomas C, Albrecht RF. Dexmedetomidine improves neurologic outcome from incomplete ischemia in the rat. Reversal by the alpha 2-adrenergic antagonist atipamezole. Anesthesiology 1991, 75:328-332. 10.1097/00000542-199108000-00022, 1677549.
5. Dahmani S, Rouelle D, Gressens P, Mantz J. Characterization of the postconditioning effect of dexmedetomidine in mouse organotypic hippocampal slice cultures exposed to oxygen and glucose deprivation. Anesthesiology 2010, 112:373-383. 10.1097/ALN.0b013e3181ca6982, 20098140.
6. Engelhard K, Werner C, Eberspacher E, Bachl M, Blobner M, Hildt E, Hutzler P, Kochs E. The effect of the alpha 2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg 2003, 96:524-531.
7. Sato K, Kimura T, Nishikawa T, Tobe Y, Masaki Y. Neuroprotective effects of a combination of dexmedetomidine and hypothermia after incomplete cerebral ischemia in rats. Acta Anaesthesiol Scand 2010, 54:377-382. 10.1111/j.1399-6576.2009.02139.x, 19860751.
8. Dahmani S, Paris A, Jannier V, Hein L, Rouelle D, Scholz J, Gressens P, Mantz J. Dexmedetomidine increases hippocampal phosphorylated extracellular signal-regulated protein kinase 1 and 2 content by an alpha 2-adrenoceptor-independent mechanism: evidence for the involvement of imidazoline I1 receptors. Anesthesiology 2008, 108:457-466. 10.1097/ALN.0b013e318164ca81, 18292683.
9. Toborek M, Son KW, Pudelko A, King-Pospisil K, Wylegala E, Malecki A. ERK 1/2 signaling pathway is involved in nicotine-mediated neuroprotection in spinal cord neurons. J Cell Biochem 2007, 100:279-292. 10.1002/jcb.21013, 16888810.
10. Shen J, Wu Y, Xu JY, Zhang J, Sinclair SH, Yanoff M, Xu G, Li W, Xu GT. ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD. Invest Ophthalmol Vis Sci 2010, 51:35-46. 10.1167/iovs.09-3544, 19628748.
11. Troadec JD, Marien M, Mourlevat S, Debeir T, Ruberg M, Colpaert F, Michel PP. Activation of the mitogen-activated protein kinase (ERK(1/2)) signaling pathway by cyclic AMP potentiates the neuroprotective effect of the neurotransmitter noradrenaline on dopaminergic neurons. Mol Pharmacol 2002, 62:1043-1052. 10.1124/mol.62.5.1043, 12391266.
12. Loetscher PD, Rossaint J, Rossaint R, Weis J, Fries M, Fahlenkamp A, Ryang YM, Grottke O, Coburn M. Argon: neuroprotection in in vitro models of cerebral ischemia and traumatic brain injury. Crit Care 2009, 13:R206. 10.1186/cc8214, 2811924, 20017934.
13. Rossaint J, Rossaint R, Weis J, Fries M, Rex S, Coburn M. Propofol: neuroprotection in an in vitro model of traumatic brain injury. Crit Care 2009, 13:R61. 10.1186/cc7795, 2689510, 19397790.
14. Stoppini L, Buchs PA, Muller D. A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 1991, 37:173-182. 10.1016/0165-0270(91)90128-M, 1715499.
15. Adamchik Y, Frantseva MV, Weisspapir M, Carlen PL, Perez Velazquez JL. Methods to induce primary and secondary traumatic damage in organotypic hippocampal slice cultures. Brain Res Brain Res Protoc 2000, 5:153-158. 10.1016/S1385-299X(00)00007-6, 10775835.
16. Coburn M, Maze M, Franks NP. The neuroprotective effects of xenon and helium in an in vitro model of traumatic brain injury. Crit Care Med 2008, 36:588-595. 10.1097/01.CCM.0B013E3181611F8A6, 18216607.
17. Roehl AB, Hein M, Loetscher PD, Rossaint J, Weis J, Rossaint R, Coburn M. Neuroprotective properties of levosimendan in an in vitro model of traumatic brain injury. BMC Neurol 2010, 10:97. 10.1186/1471-2377-10-97, 2978146, 20964834.
18. Laudenbach V, Mantz J, Lagercrantz H, Desmonts JM, Evrard P, Gressens P. Effects of alpha(2)-adrenoceptor agonists on perinatal excitotoxic brain injury: comparison of clonidine and dexmedetomidine. Anesthesiology 2002, 96:134-141. 10.1097/00000542-200201000-00026, 11753013.
19. Ma D, Hossain M, Rajakumaraswamy N, Arshad M, Sanders RD, Franks NP, Maze M. Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol 2004, 502:87-97. 10.1016/j.ejphar.2004.08.044, 15464093.
20. Paris A, Mantz J, Tonner PH, Hein L, Brede M, Gressens P. The effects of dexmedetomidine on perinatal excitotoxic brain injury are mediated by the alpha2A-adrenoceptor subtype. Anesth Analg 2006, 102:456-461. 10.1213/01.ane.0000194301.79118.e9, 16428542.
21. Sanders RD, Sun P, Patel S, Li M, Maze M, Ma D. Dexmedetomidine provides cortical neuroprotection: impact on anaesthetic-induced neuroapoptosis in the rat developing brain. Acta Anaesthesiol Scand 2010, 54:710-716.
22. Hua Y, Hisano K, Morimoto Y. Effect of mild and moderate hypothermia on hypoxic injury in nearly pure neuronal culture. J Anesth 2010, 24:726-732. 10.1007/s00540-010-0999-x, 20683733.
23. Mueller-Burke D, Koehler RC, Martin LJ. Rapid NMDA receptor phosphorylation and oxidative stress precede striatal neurodegeneration after hypoxic ischemia in newborn piglets and are attenuated with hypothermia. Int J Dev Neurosci 2008, 26:67-76. 10.1016/j.ijdevneu.2007.08.015, 2692732, 17950559.
24. The hypothermia after cardiac arrest study group Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002, 346:549-556. The hypothermia after cardiac arrest study group.
25. Tasker RC, Coyle JT, Vornov JJ. The regional vulnerability to hypoglycemia-induced neurotoxicity in organotypic hippocampal culture: protection by early tetrodotoxin or delayed MK-801. J Neurosci 1992, 12:4298-4308.
26. Finley M, Fairman D, Liu D, Li P, Wood A, Cho S. Functional validation of adult hippocampal organotypic cultures as an in vitro model of brain injury. Brain Res 2004, 1001:125-132. 10.1016/j.brainres.2003.12.009, 14972661.
27. Muller D, Buchs PA, Stoppini L. Time course of synaptic development in hippocampal organotypic cultures. Brain Res Dev Brain Res 1993, 71:93-100.
28. Morrison B, Saatman KE, Meaney DF, McIntosh TK. In vitro central nervous system models of mechanically induced trauma: a review. J Neurotrauma 1998, 15:911-928. 10.1089/neu.1998.15.911, 9840765.
29. Noraberg J, Poulsen FR, Blaabjerg M, Kristensen BW, Bonde C, Montero M, Meyer M, Gramsbergen JB, Zimmer J. Organotypic hippocampal slice cultures for studies of brain damage, neuroprotection and neurorepair. Curr Drug Targets CNS Neurol Disord 2005, 4:435-452. 10.2174/1568007054546108, 16101559.